Laboratory Issues

Dorn Spinal Therapy

Spine Healing Therapy

Get Instant Access

Several molecular pathology laboratories offer DNA testing for SBMA. The PCR test is accurate and inexpensive to perform, and requires only a blood sample. PCR with electrophoretic analysis of the PCR products allows for accurate assessment of the repeat size. External proficiency testing is not available for SBMA.

References

1. Emery AEH. Muscle histology and creatine kinase levels in the fetus in Duchenne muscular dystrophy. Nature. 1977;266:472-473.

2. Moser H. Duchenne muscular dystrophy: pathogenetic aspects and genetic prevention. Hum Genet. 1984;66:17-34.

3. Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51:919-928.

4. Koenig M, Hoffman EP, Bertelson CJ, et al. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell. 1987;50:509-517.

5. Ahn AH, Kunkel LM. The structural and functional diversity of dystrophin. Nat Genet. 1993;3:283-287.

6. Hoffman EP, Fischbeck K, Brown RH, et al. Dystrophin characterization in muscle biopsies from Duchenne and Becker muscular dystrophy patients. N Eng J Med. 1988;318:1363-1368.

7. Darras BT, Blattner P, Harper JF, et al. Intragenic deletions in 21 Duchenne muscular dystrophy (DMD)/Becker muscular dystrophy (BMD) families studied with the dystrophin cDNA: location of breakpoints on HindIII and Bglll exon-containing fragment maps, meiotic and mitotic origin of mutations. Am J Hum Genet. 1988;43: 620-629.

8. Forrest SM, Cross GS, Flint T, et al. Further studies of gene deletions that cause Duchenne and Becker muscular dystrophies. Genomics. 1988;2:109-117.

9. Monaco AP, Bertelson CJ, Liechti-Gallati S, et al. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics. 1988;2:90-95.

10. Roberts RG, Gardner RJ, Bobrow M. Searching for the 1 in 2,400,000: a review of dystrophin gene point mutations. Hum Mutat. 1994;4: 1-11.

11. Prior TW, Papp AC, Snyder PJ, et al. A missense mutation in the dys-trophin gene in a Duchenne muscular dystrophy patient. Nat Genet. 1993;4:357-361.

12. Prior TW, Bartolo C, Pearl DK, et al. Spectrum of small mutations in the dystrophin coding region. Am J Hum Genet. 1995;57:22-33.

13. Prior TW, Friedman KJ, Highsmith WE, et al. Molecular probe protocol for determining carrier status in Duchenne and Becker muscular dystrophies. Clin Chem. 1990;36:441-446.

14. Chamberlain JS, Gibbs RA, Ranier JE, et al. Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification. Nucleic Acids Res. 1988;16:11141-11156.

15. Clemens PR, Fenwick RG, Chamberlain JS, et al. Carrier detection and prenatal diagnosis in Duchenne and Becker muscular dystrophy families, using dinucleotide repeat polymorphisms. Am J Hum Genet. 1991;49:951-958.

16. Bakker E,Van Broeckhoven C, Bonten EJ, et al. Germline mosaicism and Duchenne muscular dystrophy mutations. Nature. 1987;329: 554-557.

17. Harper PS. Congenital myotonic dystrophy in Britain, II: genetic basis. Arch Dis Child. 1975;50:514-521.

18. Brook HG, McCurrach ME, Harley HG, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family. Cell. 1992;68:799-808.

19. Fu YH, Pizzuti A, Fenwick R, et al. An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science. 1992;255:1256-1258.

20. Mahadevan M, Tsilfidis C, Sabourin L, et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene. Science. 1992;255:1253-1255.

21. Fu YH, Friedman DL, Richards S, et al. Decreased expression of mytonin-protein kinase messenger RNA and protein in adult form of mytonic dystrophy. Science. 1993;260:235-238.

22. Sabouri LA, Mahadevan MS, Narang M, et al. Effect of the mytonic dystrophy mutation on mRNA levels of the DM gene. Nat Genet. 1993;4:233-238.

23. Barcelo JM, Mahadevan MS, Tsilfidis C, et al. Intergenerational stability of the myotonic dystrophy protomutation. Hum Mol Genet. 1993;2:705-709.

24. Anvret M, Ahlberg G, Grandell U, et al. Larger expansions of the CTG repeat in muscle compared to lymphocytes from patients with myotonic dystrophy. Hum Mol Genet. 1993;2:1397-1400.

25. Liquori C, Ricker K, Mosley M, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science. 2001;293;864-867.

26. Pearn J. Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. J Med Genet. 1978;15:409-413.

27. Lefebvre S, Burglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80:155-165.

28. McAndrew PE, Parsons DW, Simard LR, et al. Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number. Am J Hum Genet. 1997;60: 1411-1422.

29. Mailman MD, Heinz JW, Papp AC, et al. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med. 2002;4:20-26.

30. Velasco E, Valero C, Valero A, Moreno F, Hernandez-Chico C. Molecular analysis of the SMN and NAIP genes in Spanish spinal muscular atrophy (SMA) families and correlation between number of copies of cBCD 541 and SMA phenotype. Hum Mol Genet. 1996;5: 257-263.

31. Talbot K, Ponting CP, Theodosiou AM, et al. Missense mutation clustering in the survival motor neuron gene: a role for a conserved tyrosine and glycine rich region of the protein RNA metabolism? Hum Mol Genet. 1997;6:497-501.

32. Liu Q, Dreyruss G. A novel nuclear structure containing the survival of motor neurons protein. EMBO J. 1996;15:3355-3365.

33. Chen K-L, Wang YL, Rennert H, et al. Duplications and de novo deletions of the SMNt gene demonstrated by fluorescence-based carrier testing for spinal muscular atrophy. Am J Med Genet. 1999;85:463-469.

34. Parsons DW, McAndrew PE, Iannaccone ST, Mendell JR, Burghes AHM, Prior TW. Intragenic telSMN mutations: frequency, distribution, evidence of a founder effect, and modification of SMA phenotype by cenSMN copy number. Am J Hum Genet. 1998;63: 1712-1723.

35. Wirth B, Rudnik-Schoneborn S, Hahnen E, et al. Prenatal prediction in families with autosomal recessive proximal spinal muscular atrophy (5q11.2-q13.3): molecular genetics and clinical experience in 109 cases. Prenat Diagn. 1995;15:407-417.

36. Berenberg R, Pellock J, DiMauro S, et al. Lumping or splitting? "Ophthalmopelgia-plus" or Kearns-Sayre syndrome? Ann Neurol. 1977;1:37-42.

37. Moraes CT, DiMauro S, Zeviani M, et al. Mitochondrial DNA deletions in progressive external ophthalmoplegia and Kearns-Sayre syndrome. N Engl J Med. 1989;320:1293-1299.

38. Hirano M, Ricci E, Koenigsberger MR, et al. MELAS: an original case and clinical criteria for diagnosis. Neuromuscul Disord. 1992;2:125-135.

39. Goto Y, Nonaka I, Horai S. A mutation in the tRNALeu (UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature. 1990;348:651-653.

40. Silvestri G, Ciafaloni E, Santorelli FM, et al. Clinical features associated with the A ^ G transition at nucleotide 8344 of mtDNA ("MERRF mutation"). Neurology. 1993;43:1200-1206.

41. Kennedy WR, Alter M, Sung JH. Progressive proximal spinal and bulbar muscular atrophy of late onset: a sex-linked recessive trait. Neurology. 1968;18:671-680.

42. La Spada AR, Wilson AR, Lubahn DB. Androgen receptor mutations in X-linked spinal muscular atrophy. Nature. 1991;353:77-79.

43. Amato AA, Prior TW, Barohn R, Snyder P, Papp A, Mendell JR. Kennedy's disease: a clinicopathologic correlation with mutations in the androgen receptor gene. Neurology. 1993;43:791-794.

Was this article helpful?

0 0

Post a comment